These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29177732)

  • 1. DNA Topoisomerases as Targets for Antibacterial Agents.
    Hiasa H
    Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
    Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
    PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
    Tse-Dinh YC
    Future Med Chem; 2016 Jun; 8(10):1085-100. PubMed ID: 27285067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
    Badshah SL; Ullah A
    Eur J Med Chem; 2018 May; 152():393-400. PubMed ID: 29751233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
    Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
    J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
    Kokot M; Anderluh M; Hrast M; Minovski N
    J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity.
    Desai J; Patel B; Panchal N; Gite A; Darji B; Viswanathan K; Trivedi J; Vyas P; Pawar V; Giri P; S S; Sharma R; Jain M; Iyer P; Kumar S
    Bioorg Med Chem Lett; 2024 Oct; 111():129911. PubMed ID: 39067715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
    Ho SY; Wang W; Ng FM; Wong YX; Poh ZY; Tan SWE; Ang SH; Liew SS; Joyner Wong YS; Tan Y; Poulsen A; Pendharkar V; Sangthongpitag K; Manchester J; Basarab G; Hill J; Keller TH; Cherian J
    Eur J Med Chem; 2018 Sep; 157():610-621. PubMed ID: 30125722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.
    Tomašić T; Mašič LP
    Curr Top Med Chem; 2014; 14(1):130-51. PubMed ID: 24236722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
    Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
    Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents.
    Durcik M; Tomašič T; Zidar N; Zega A; Kikelj D; Mašič LP; Ilaš J
    Expert Opin Ther Pat; 2019 Mar; 29(3):171-180. PubMed ID: 30686070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
    Metwally NH; Abdallah SO; Mohsen MMA
    Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs).
    Kolarič A; Anderluh M; Minovski N
    J Med Chem; 2020 Jun; 63(11):5664-5674. PubMed ID: 32027491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of secondary metabolites from Crescentia cujete as promising antibacterial therapeutics targeting type 2A topoisomerases through molecular dynamics simulation.
    Aribisala JO; Abdulsalam RA; Dweba Y; Madonsela K; Sabiu S
    Comput Biol Med; 2022 Jun; 145():105432. PubMed ID: 35344868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.
    Magarò G; Prati F; Garofalo B; Corso G; Furlotti G; Apicella C; Mangano G; D'Atanasio N; Robinson D; Di Giorgio FP; Ombrato R
    J Med Chem; 2019 Aug; 62(16):7445-7472. PubMed ID: 31276392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.
    Azam MA; Thathan J; Jubie S
    Bioorg Chem; 2015 Oct; 62():41-63. PubMed ID: 26232660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.